The Veterinary Resources Support Facility is operated out of the Department of Veterinary Sciences, a component of the M.D. Anderson Science Park. This CCSG-support CORE facility provides a cost-effective, Cancer Center-wide Rodent Serology Program that supports the health of rodent research colonies and the operation of SPF facilities throughout the institution, where utilization approaches 100,000 rodents per year. At the Science Park campus, serology and other forms of health and genetic assessment comprise the Rodent Health and Genetic Quality Assurance Program, integral to maintenance of 14,500 SPF rodents and the numerous inbred and transgenic breeding production colonies maintained at that campus. These programs provide animal health information that is vital to the utilization of defined animal models that are free of intercurrent disease or silent infections. These goals are particularly critical for complex cancer models in areas such as carcinogenesis, chemoprevention, and gene-, immuno-, biological-, and radio-therapy. The Veterinary Resources Support Facility also provides a clinical veterinarian (65%) that oversees the rodent facilities at both Science Park campuses, provides specialized research services, managed breeding production colonies, and assists MDACC investigators with custom polyclonal antisera production (cost recovered). We are requesting new funds to provide investigators with assistance in transgenic breeding management and PCR sample collection as part of the services of producing transgenic animals. An electronic communique for institutional transgenic users and mechanisms for re-deriving imported transgenics harboring pathogens will also be established.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-25
Application #
6334923
Study Section
Project Start
2000-07-18
Project End
2001-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
25
Fiscal Year
2000
Total Cost
$332,337
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Garg, Rachana; Blando, Jorge M; Perez, Carlos J et al. (2018) COX-2 mediates pro-tumorigenic effects of PKC? in prostate cancer. Oncogene 37:4735-4749
Flinn, Ian W; O'Brien, Susan; Kahl, Brad et al. (2018) Duvelisib, a novel oral dual inhibitor of PI3K-?,?, is clinically active in advanced hematologic malignancies. Blood 131:877-887
Subbiah, Ishwaria M; Tang, Chad; Rao, Arvind et al. (2018) Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget 9:28842-28848
Daver, Naval; Boddu, Prajwal; Garcia-Manero, Guillermo et al. (2018) Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 32:1094-1105
Bailey, Matthew H; Tokheim, Collin; Porta-Pardo, Eduard et al. (2018) Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173:371-385.e18
Ohri, Nisha; Sittig, Mark P; Tsai, Chiaojung Jillian et al. (2018) Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis. Cancer 124:482-490
Cao, Qizhen; Yan, Xinrui; Chen, Kai et al. (2018) Macrophages as a potential tumor-microenvironment target for noninvasive imaging of early response to anticancer therapy. Biomaterials 152:63-76
Vichaya, Elisabeth G; Dantzer, Robert (2018) Inflammation-induced motivational changes: Perspective gained by evaluating positive and negative valence systems. Curr Opin Behav Sci 22:90-95
Nguyen, Jennifer; Jiao, Jingjing; Smoot, Kristin et al. (2018) Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis. Oncotarget 9:29495-29507
Reddy, S M; Barcenas, C H; Sinha, A K et al. (2018) Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer 118:17-23

Showing the most recent 10 out of 12418 publications